last three years, year-wise and company-wise are given below:

Name of drug/Company	A/C Unit	Capacity	Production		
			1985-86	1986-87	1987-88
DIAZEPAM	MTT				
1. Ranbaxy Labs. . . .		4	0.65	0.81	1.03
2. Roche Products . . .		0.38	0.03	..	0.99
3. Fairdeal Corpn. . . .		1.0	0.43	8.03	8.11
4. Anglo French		0.50	..	..	0.21

(c) to (f) Names of drugs and the quantities imported are published in the Monthly Statistics for foreign Trade in India Vol. II, copies of which are available in the Parliament Library. The import policy of a drug is determined in consideration of several factors such as demand and availability, technology etc.

(g) Diazepam has been excluded from price control as per recommendations of the Kelkar Committee contained in their supplementary report.

(h) Sales turnover of formulations is not monitored.

Price Revision of Drugs

2433. PROF. C. LAKSHMANNA:

SHRI DAYANAND SAHAY:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 129 given in the Rajya Sabha on the 24th April, 1989 and state:

(a) whaf were the prices arrived at initially after review of the plea by the producers of Dexarnethasone; Betamethasone, Glybenclamide, Baralgon, Ketone and Tetracycline!

(b) whether it is a fact that the prices were changed;

(c) if so, when and what were the ' prices arrived at finally;

(d) whether it is a fact that the prices approved initially were based on BICP report;

(e) if so, what was the price recommended by BICP for each drug;

(f) on what basis the prices have been increased and whether these are based on BICP recommendation; and

(g) If so, what are the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS .IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (g) Detailed information shall be laid on the Table of the Rajya Sabha after the Price Review Committee and Spe» cial Team have completed all their work.